BFC
SRNE

Bedel Financial Consulting’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Bedel Financial Consulting’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,480
Closed -$3K – 989
2022
Q1 		$3K Hold
1,480
– – ﹤0.01% 861
2021
Q4 		$7K Buy
+1,480
New +$9.19K ﹤0.01% 741

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bedel Financial Consulting's SRNE Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2022, closing a stake of 1,480 shares — an estimated $3K sold.

Bedel Financial Consulting first reported a position in SRNE in Q4 2021 and held it in 2 quarters. The position peaked at $7K in Q4 2021. 229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

  • Bedel Financial Consulting reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 1,480 Sorrento Therapeutics, Inc. shares in Q2 2022, an estimated $3K.
  • Bedel Financial Consulting first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 2 quarters.
  • Bedel Financial Consulting's Sorrento Therapeutics, Inc. position peaked at $7K in Q4 2021.
  • 229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.